Drugs / BIAsp 30
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT01889095 | Jul → Aug 2011 | type 2 diabetes mellitus | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00283218 | Jan → Aug 2006 | type 1 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03018665 Comparator | Feb 2017 → Dec 2021 | type 2 diabetes mellitus | The First Hospital of Jilin University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIAsp30 | “The profiles will be derived over a 12-hour period after subcutaneous injection in the abdominal region with a single dose of IAsp, BIAsp 30, BIAsp 50 or BIAsp 70 at a test meal.” NCT00283218 ↗ |
| Known as | NovoMix 30-pen | “The starting dose of BIAsp 30 (NovoMix® 30-pen, NovoNordisk) was 0.2-0.6 unit/kg per day in 2 divided doses according to level of glycemia in the intervention group.” NCT01889095 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT03018665 ↗ |